ArticleHCA healthcare journal of medicine2025
An Unusual Presentation of Lichen Planus Pigmentosus Inversus Responsive to Topical Tacrolimus: A Case Report.
Article in HCA healthcare journal of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lichen planus pigmentosus inversus (LPPI) is a rare variant of lichen planus pigmentosus (LPP), characterized by sharply defined violaceous-brown to gray macules, papules, patches, or plaques primarily affecting the intertriginous and flexural areas. Unlike LPP, which predominantly affects Fitzpatrick skin types III to IV in sun-exposed areas, LPPI spares these regions and has been predominantly reported in White and Asian patients. Case Presentation: We discuss a 66-year-old man with Fitzpatrick skin type III who presented with a year-long history of mildly itchy, hyperpigmented plaques on the inframammary folds. These plaques developed after being hospitalized for a chronic urinary tract infection that was treated with antibiotics. He felt self-conscious and anxious due to the changes in skin, which affected his quality of life. His medical history included controlled diabetes and dyslipidemia, and he reported no systemic symptoms or prior topical medication use. A physical examination revealed well-demarcated, violaceous-brown plaques without scaling. Tests for fungal organisms, antinuclear antibodies, thyroid function, and hepatitis C were negative, and routine blood work was normal. A biopsy confirmed LPPI. Initial treatments with triamcinolone were ineffective, and hydroquinone was discontinued after 2 weeks due to irritation. The patient improved with tacrolimus 0.1% ointment twice daily, showing significant reduction in hyperpigmentation and improvement in skin texture at 4 and 8 weeks, with no side effects noted. Conclusion: This case report highlights the diagnostic and therapeutic challenges associated with LPPI and discusses its potential response to topical tacrolimus. Our findings indicate that tacrolimus 0.1% ointment provides a safe and effective nonsteroidal treatment alternative for LPPI. Given the possible impact of LPPI on quality of life, timely diagnosis and appropriate management are crucial. Due to the absence of established treatment protocols for LPPI, further studies are necessary to better understand treatment responses and guide therapeutic strategies, particularly for individuals with darker skin tones.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.